Journal: Biomolecules

Article Title: Palmitic Acid Esterification Boosts Epigallocatechin Gallate’s Immunomodulatory Effects in Intestinal Inflammation

doi: 10.3390/biom15081208

Figure Lengend Snippet: Dot plots of representative pro-inflammatory (CD86-Coralite ® Plus 647, M1) and propidium iodide double stains of M0 macrophages (differentiated from THP-1 monocytic cells treated with Phorbol-Myristate Acetate) exposed to pro-inflammatory growth media of Caco-2 cells in the presence/absence of epigallocatechin gallate and palmitoyl epigallocatechin gallate. Distinct lowercase letters indicate significantly different values at p < 0.05 according to one-way analyses of variance (ANOVA) and Duncan’s multiple range test ( n = 3).

Article Snippet: CoraLite ® Plus 647 Anti-Human CD86 and CD206 antibodies were obtained from Proteintech ® (ThermoFisher Scientific, Madrid, Spain; Catalog #CL647-65165 and #CL647-65155, respectively).

Techniques:

Journal: eLife

Article Title: Short-range interactions between fibrocytes and CD8 + T cells in COPD bronchial inflammatory response

doi: 10.7554/eLife.85875

Figure Lengend Snippet:

Article Snippet: Antibody , Anti-IL-17-PE-Cy7 (mouse monoclonal) , Miltenyi Biotec , Cat. #:130-120-413, RRID: AB_2752086 , FC (1:20).

Techniques: Blocking Assay, Recombinant

Journal: International Journal of Molecular Sciences

Article Title: Effects of PACAP Deficiency on Immune Dysfunction and Peyer’s Patch Integrity in Adult Mice

doi: 10.3390/ijms251910676

Figure Lengend Snippet: Fluorochrome conjugated monoclonal antibodies used in the study.

Article Snippet: GranzymeB , FITC , REA226 , recombinant human IgG1 , Miltenyi Biotec. , 130-118-341.

Techniques: Bioprocessing, Recombinant

Journal: Frontiers in Pharmacology

Article Title: Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17–mediated inflammation

doi: 10.3389/fphar.2026.1754729

Figure Lengend Snippet: Integrated workflow for target prediction and experimental validation of Lico B in psoriasis. Bioinformatic analyses, including WGCNA module construction, gene–trait correlation analysis, multi-database target intersection (GEO, GeneCards, TTD), molecular docking, and SPR analysis were used to identify candidate targets of Lico B. Subsequent in vitro and in vivo experiments—comprising Western blotting, qPCR, immunofluorescence staining, and flow cytometry in IL-17–stimulated keratinocytes and IMQ-induced psoriatic mice—were conducted to validate the therapeutic mechanisms of Lico B.

Article Snippet: The IL-17 group was treated with 100 ng/mL IL-17 (Proteintech; HZ-1113); the Lico B group received 9 μM Lico B (MCE; HY-N3388); the IL-17 + Lico B group was co-treated with IL-17 and Lico B; and the control group was treated with PBS.

Techniques: Biomarker Discovery, In Vitro, In Vivo, Western Blot, Immunofluorescence, Staining, Flow Cytometry

Journal: Frontiers in Pharmacology

Article Title: Licoisoflavone B alleviates psoriasis via SCD1-targeted lipid metabolism reprogramming and suppression of Th17/IL-17–mediated inflammation

doi: 10.3389/fphar.2026.1754729

Figure Lengend Snippet: Schematic illustration of lico B treatment in psoriasis. Lico B modulates lipid metabolic pathways by suppressing SCD1-dependent metabolic reprogramming and reducing lipid droplet accumulation in keratinocyte, while simultaneously attenuating the TH17/IL-17 axis. Through concurrent regulation of keratinocyte metabolism and inflammatory cytokine production, Lico B ameliorate psoriatic skin pathology.

Article Snippet: The IL-17 group was treated with 100 ng/mL IL-17 (Proteintech; HZ-1113); the Lico B group received 9 μM Lico B (MCE; HY-N3388); the IL-17 + Lico B group was co-treated with IL-17 and Lico B; and the control group was treated with PBS.

Techniques: